SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
To determine the activity of SCH 727965 in participants with breast cancer and in
participants with nonsmall-cell lung cancer (NSCLC) compared to standard treatment. The
standard treatment used is capecitabine for breast cancer and erlotinib for NSCLC. The study
will also determine the activity of SCH 727965 treatment in participants who experience
cancer progression after standard treatment.